Aratana Therapeutics Inc (PETX, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Aratana Therapeutics Inc is a pet therapeutics company. Its main activity is the licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals. Aratana Therapeutics Inc has a market cap of $187.200 million; its shares were traded at around $3.85 with and P/S ratio of 4.28. Aratana Therapeutics Inc had annual average EBITDA growth of 33.60% over the past five years.
For the last quarter Aratana Therapeutics Inc reported a revenue of $21.6 million, compared with the revenue of $6.16 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $35.4 million, an increase of 38.5% from last year. For the last five years Aratana Therapeutics Inc had an average revenue growth rate of 240.4% a year.
The reported loss per diluted share was 32 cents for the year, compared with the loss per share of $1.3 in the previous year. The Aratana Therapeutics Inc had an operating margin of -33.57%, compared with the operating margin of -144.72% a year before. The 10-year historical median operating margin of Aratana Therapeutics Inc is -5424.90%. The profitability rank of the company is 3 (out of 10).
At the current stock price of $3.85, Aratana Therapeutics Inc is traded at 84% discount to its historical median P/S valuation band of $24.00. The P/S ratio of the stock is 4.28, while the historical median P/S ratio is 26.79. The stock lost 13.09% during the past 12 months.
For the complete 20-year historical financial data of PETX, click here.
